IDEAYA Biosciences Announces 10-Year Anniversary R&D Day on September 8, 2025 to Present Multiple Clinical Data Updates and Outline Future Growth Strategy
Rhea-AI Summary
IDEAYA Biosciences (Nasdaq: IDYA) has announced its upcoming 10-Year Anniversary R&D Day, scheduled for September 8, 2025, from 8:00 AM to 10:00 AM ET in New York City. The event will be accessible both in-person and virtually.
The R&D Day will feature presentations of multiple clinical data updates across the company's pipeline, along with discussions about future growth drivers and upcoming milestones. The event will include presentations from IDEAYA's senior leadership team and key opinion leaders in precision medicine oncology.
CEO Yujiro S. Hata will outline the company's strategic vision, priority scientific focus areas, and emerging clinical pipeline as IDEAYA positions itself as a global leader in precision medicine oncology.
Positive
- None.
Negative
- None.
News Market Reaction – IDYA
On the day this news was published, IDYA gained 7.31%, reflecting a notable positive market reaction. Argus tracked a peak move of +3.7% during that session. Our momentum scanner triggered 30 alerts that day, indicating elevated trading interest and price volatility. This price movement added approximately $152M to the company's valuation, bringing the market cap to $2.24B at that time.
Data tracked by StockTitan Argus on the day of publication.
"This year marks IDEAYA's ten-year anniversary since our founding, and we look forward to providing multiple clinical data updates across our potential first-in-class pipeline, and highlight our strategic vision, priority areas of scientific focus, and emerging clinical pipeline that will drive the next phase of our growth as a global leader in precision medicine oncology," said Yujiro S. Hata, President and Chief Executive Officer, IDEAYA Biosciences.
Speakers will include members of IDEAYA's senior leadership team and key opinion leader(s).
Registration for this event can be accessed here or at the investors section of the IDEAYA website at https://ir.ideayabio.com/events.
About IDEAYA Biosciences
IDEAYA is a precision medicine oncology company committed to the discovery, development, and commercialization of transformative therapies to address unmet medical needs in cancer. The company integrates small molecule drug discovery, structural biology and bioinformatics with extensive capabilities in identifying and validating translational biomarkers to develop potentially first-in-class targeted therapies for selected patient populations. IDEAYA has built a robust pipeline of targeted therapies focused on synthetic lethality and antibody-drug conjugates, or ADCs, including bispecifics, with the goal of improving clinical outcomes for patients with cancer.
Forward-Looking Statements
This press release contains forward-looking statements, including, but not limited to, statements related to participation in and/or presentation at a certain investor relation event. IDEAYA undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of IDEAYA in general, see IDEAYA's current and future filings with the
Investor and Media Contact
IDEAYA Biosciences
Joshua Bleharski, Ph.D.
Chief Financial Officer
investor@ideayabio.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/ideaya-biosciences-announces-10-year-anniversary-rd-day-on-september-8-2025-to-present-multiple-clinical-data-updates-and-outline-future-growth-strategy-302510199.html
SOURCE IDEAYA Biosciences, Inc.
FAQ
When is IDEAYA Biosciences (IDYA) R&D Day 2025 and how can investors attend?
What will be presented at IDEAYA Biosciences' (IDYA) 2025 R&D Day?
Who will be speaking at IDEAYA's (IDYA) 2025 R&D Day?
How can I access IDEAYA Biosciences' (IDYA) R&D Day presentation?
